Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well ibrutinib works in treating patients with stage IV
melanoma of the skin that has not responded to previous treatment. Ibrutinib may stop the
growth of tumor cells by blocking some of the enzymes needed for cell growth.